Omalizumab, for example, which prevents IgE binding to FcεRI and FcεRII (CD23), reduces asthma exacerbations and mucosal inflammation at least in atopic asthmatics, and its possible effects in nonatopic asthma remain to be seen. Here, FCER2 is linked to asthma.